Therapy Program

Prophase Labs

06/02/2023 16:59

Feb 6 (Reuters) - Prophase Labs Inc  PRPH.O :
    * PROPHASE LABS PROVIDES UPDATE ON LINEBACKER-1 CANCER
CO-THERAPY
PROGRAM AND OUTLINES DEVELOPMENT STRATEGY
    * PROPHASE LABS PROVIDES UPDATE ON LINEBACKER-1 CANCER
CO-THERAPY
PROGRAM AND OUTLINES DEVELOPMENT STRATEGY
    * PROPHASE LABS INC - AIMS TO SUBMIT ITS IND APPLICATION FOR
LINEBACKER-1 IN MID-2024
    * PROPHASE LABS INC -  WE ADVANCE TOWARD A POTENTIAL IND
APPLICATION SUBMISSION IN MID-2024
    * PROPHASE LABS INC - GOAL FOR COMPLETION OF ANIMAL STUDIES
IS END
OF Q2 2023, WITH DATA EXPECTED TO BE PUBLISHED IN Q3 2023
    * PROPHASE LABS INC - INITIAL GMP MANUFACTURING FOR LB-1 IS
EXPECTED TO KICK OFF IN Q3 OF 2023, IN TANDEM WITH TOXICOLOGY
STUDIES
    * PROPHASE LABS - SELECTION HAS BEEN CONFIRMED FOR ANIMAL
STUDIES;
DANA-FARBER/HARVARD TO DEPLOY TWO ANIMAL XENOGRAFT MODELS, WITH
AND WITHOUT RADIATION

Source text for Eikon:  ID:nGNX8gzs8Z 
Further company coverage:  PRPH.O 
 ((Reuters.Briefs@thomsonreuters.com;))